Xspray Pharma strengthens the organization with IR and Communications function

Press release 2021-11-15

Xspray Pharma AB (publ) (Nasdaq Stockholm: XSPRAY) today announces that the company is strengthening its organization by creating an Investor Relations and Communications function. Christina Malmberg Hägerstrand has been appointed Vice President and Head of Investor Relations and Communications, she joins Xspray Pharma in January 2022.

“With the development of Xspray Pharma and the initial phase of commercialization, the need to communicate with various stakeholders has grown significantly. I am very pleased that Christina has chosen to accept this new position. Her experience from global listed companies and heavily regulated sectors in combination with a solid academic background means we are now ready to implement a more strategic approach in the development of the company's communication and investor relations going forward”, says Per Andersson, CEO Xspray Pharma.

With extensive experience in corporate communication, media relations and financial communication, Christina Malmberg Hägerstrand joins from her current role as Director of External Communication at AstraZeneca AB. She has previously held positions as Head of Communications at Nasdaq Nordic and Baltic and Head of External Communications at Alecta.

Christina holds an LL.M. in Law from Stockholm University. She is also a trained journalist and has worked at Dagens Industri and news agency Infront Direkt.

“I am proud to have been entrusted to take Xspray Pharma to the next level in strategic communication and investor relations. The company has an exciting business concept and product portfolio, now Xspray Pharma is in a phase where communication will play a crucial role. I look forward to contributing to the company's continued success", says Christina Malmberg Hägerstrand.

Christina will join Xspray Pharma on January 10, 2022 and will be part of the executive team.

About Xspray Pharma

Xspray Pharma AB (publ) is a pharmaceutical company with several product candidates in clinical development. Xspray Pharma uses its innovative, patented RightSize™ technology to develop improved and generic versions of marketed drugs, primarily protein kinase inhibitors (PKIs) for the treatment of cancer. The segment is the second largest in oncology, and drug prices are very high.

The company´s innovative technology allows Xspray Pharma to gain entry as the first competitor to today’s original drugs before the secondary patents expire. Xspray’s goal is to become the leader in the development of improved drugs or generic versions of PKIs already marketed for the treatment of cancer, which numbered to 68 in the beginning of 2021. The company’s leading product candidates, HyNap-Dasa, HyNap-Nilo, and HyNap-Sora, are stable amorphous versions of the three blockbuster cancer drugs Sprycel® (dasatinib), Tasigna® (nilotinib) and Nexavar® (sorafenib). HyNap-Dasa is being developed as an improved version of Sprycel. HyNap-Nilo is being developed as an improved version of Tasigna and has has received orphan drug status from the US FDA. HyNap-Sora is being developed as an improved version of Nexavar®.

The company has patented manufacturing technology, equipment, and the resulting products. The shares in Xspray Pharma are traded on Nasdaq Stockholm (Nasdaq Stockholm: XSPRAY).
www.xspraypharma.com